Comparison of prophylactic naftopidil, tamsulosin, and silodosin for (125)I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: Randomized controlled trial - Abstract

Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

 

To compare the efficacy of three α(1A)/α(1D)-adrenoceptor (AR) antagonists-naftopidil, tamsulosin, and silodosin-that have differing affinities for the α(1)-AR subtypes in treating urinary morbidities in Japanese men with (125)I prostate implantation (PI) for prostate cancer.

This single-institution prospective randomized controlled trial compared naftopidil, tamsulosin, and silodosin in patients undergoing PI. Patients were randomized and received either naftopidil, tamsulosin, or silodosin. Treatment began 1 day after PI and continued for 1 year. The primary efficacy variables were the changes in total International Prostate Symptom Score (IPSS) and postvoid residual urine (PVR). The secondary efficacy variables were changes in IPSS storage score and IPSS voiding score from baseline to set points during the study (1, 3, 6, and 12 months).

Two hundred twelve patients were evaluated in this study between June 2006 and February 2009: 71, 70, and 71 patients in the naftopidil, tamsulosin, and silodosin groups, respectively. With respect to the primary efficacy variables, the mean changes in the total IPSS at 1 month after PI in the naftopidil, tamsulosin, and silodosin groups were +10.3, +8.9, and +7.5, respectively. There were significantly greater decreases with silodosin than naftopidil at 1 month in the total IPSS. The mean changes in the PVR at 6 months were +14.6, +23.7, and +5.7 mL in the naftopidil, tamsulosin, and silodosin groups, respectively; silodosin showed a significant improvement in the PVR at 6 months vs. tamsulosin. With respect to the secondary efficacy variables, the mean changes in the IPSS voiding score at 1 month in the naftopidil, tamsulosin, and silodosin groups were +6.5, +5.6, and +4.5, respectively; silodosin showed a significant improvement in the IPSS voiding score at 1 month vs. naftopidil.

Silodosin has a greater impact on improving PI-induced lower urinary tract symptoms than the other two agents.

Written by:
Tsumura H, Satoh T, Ishiyama H, Tabata KI, Kotani S, Minamida S, Kimura M, Fujita T, Matsumoto K, Kitano M, Hayakawa K, Baba S.   Are you the author?

Reference: Int J Radiat Oncol Biol Phys. 2011 Jun 8. Epub ahead of print.
doi: 10.1016/j.ijrobp.2011.04.026

PubMed Abstract
PMID: 21664068

UroToday.com Prostate Cancer Section

 

 

email news signup